SOUTH KOREA,
Sept. 1, 2021
/CNW/ - OncoQuest Pharmaceuticals Inc., ("OncoQuest") a
clinical-stage biopharmaceutical company focused on the development
and commercialization of immunotherapies for cancer, today
announces the first patient enrolled in each of two investigator
initiated clinical trials assessing the safety and efficacy of
oregovomab in a previously treated recurrent ovarian cancer
setting.
The first study, led byProf. Jung KH, is being conducted
at three centres in Korea (Korea Anam Hospital, Seoul St. Mary's
Hospital and Seoul Asan Hospital). This is a Phase
1b/2 clinical trial evaluation of the
safety and efficacy of oregovomab when used in combination with
bevacizumab, paclitaxel, and carboplatin in subjects with platinum
sensitive recurrent ovarian cancer. Oregovomab has previously been
established to augment the activity of carboplatin and paclitaxel
through immune stimulation, and bevacizumab augments the activity
of carboplatin and paclitaxel by inhibiting angiogenesis. The study
will establish the safety and compatibility of the combination of
these agents as possible approaches in patient
management(ClinicalTrials.gov Identifier: NCT04938583). This study
is supported by Korean Government's K-Master program (KM-21) under
the guidance of Prof. Kim
YH at the Korea University Anam
Hospital and Professor Park KH at
Korea University College of Medicine.
The second
study (ORION-02), led by
Clinical Assistant Professor Jack
Chan, is being conducted at a single centre in Singapore (National Cancer Centre Singapore).
This is a Phase 1/2 clinical trial evaluation of the
safety and efficacy of platinum-based chemotherapy, oregovomab and
the PD-1 blockade agent, nivolumab, in subjects with platinum
sensitive recurrent epithelial cancer of ovarian, tubal, or
peritoneal origin (ClinicalTrials.gov Identifier:
NCT04620954). The safety of oregovomab in combination with
nivolumab has already been established in the ORION-01 study
(ClinicalTrials.gov Identifier: NCT03100006).
OncoQuest has completed a Phase II study using oregovomab
in combination with a TLR-3 agonist (Hiltonol®) in the recurrent
ovarian cancer setting (ClinicalTrials.gov Identifier:
NCT03162562). Oregovomab is currently being tested in a global
Phase III study in 12 countries in combination with carboplatin and
paclitaxel chemotherapy in the front-line ovarian cancer setting
(ClinicalTrials.gov Identifier: NCT04498117).
"We are committed to continue to work with
investigators to explore the potential of oregovomab in combination
therapies for treating ovarian cancer in both front line and
recurrent settings. Progress in this area began in collaboration
with Dr. Alan Gordon
(Gynecologic Oncology2004 94:340-351) that identified
potential favourable interactions between oregovomab and both
carboplatin and doxorubicin in the recurrent disease setting.
Those initial results led eventually to the observations recently
reported by Brewer et al (Gynecologic Oncology 2020 156:523-529)
that combining oregovomab with carboplatin and paclitaxel in a
front-line setting improves outcomes", said Dr. Madiyalakan,
Chairman of OncoQuest. OncoQuest is also in the process of
initiating a clinical trial using oregovomab with niraparib in the
recurrent ovarian cancer setting. "These additional clinical
studies will guide us to select the optimal combinations for
treatment throughout the course of this difficult disease," added
Dr. Madiyalakan.
About Oregovomab.
Oregovomab is a murine IgG against CA 125. Indirect
immunization with oregovomab interacts with immune modulating
properties of infused paclitaxel and carboplatin resulting in
synergistic clinical benefit as observed in this phase 2
trial. In a randomized Phase 2 clinical trial of 97 patients,
treatment with Oregovomab demonstrated a highly clinically
significant outcome for both progression-free and overall survival
favoring the addition of oregovomab to a standard of care
chemotherapy combination of carboplatin and paclitaxel. The risk of
progression and of death was reduced by more than 50% when compared
to placebo, and safety data showed that oregovomab did not add
incremental toxicity to the chemotherapy regimen. Clinical and
translational results were published in Gynecologic Oncology
(2020 156:523-529) and Cancer Immunology and Immunotherapy
(2020 69: 383-397), respectively.
About OncoQuest Pharmaceuticals Inc.
OncoQuest Pharmaceuticals Inc. is a Korean
biopharmaceutical company focused on the development and
commercialization of immunotherapies for cancer. OncoQuest
Pharmaceuticals' technology platform includes a portfolio of tumor
antigen specific monoclonal immunoglobulins targeting CA-125, MUC1,
PSA and Her2/neu. The company acquired these technologies from
OncoQuest Inc. (Canada), one of
the equity investee companies of Quest PharmaTech Inc., a publicly
traded, Canadian based biopharmaceutical company (TSX-V:QPT)
www.questpharmatech.com.OncoQuest is exploring the
therapeutic potential of these antibodies as indirect immunizers in
combination with other immune modulating drugs or drug combinations
to address unmet medical needs in oncology. To learn more, visit
www.oncoquestinc.com
Forward Looking Statements
This press release includes forward-looking statements. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are
based on management's expectations and assumptions as of the date
of this press release and are subject to a number of risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. The information in this release is
provided only as of the date of this release and the company
undertakes no obligation to update any forward-looking statements
contained in this release based on new information, future events,
or otherwise, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original
content:https://www.prnewswire.com/news-releases/oncoquest-pharmaceuticals-inc-announces-first-patient-enrolled-in-each-of-two-investigator-initiated-clinical-trials-of-oregovomab-in-combination-therapy-for-the-treatment-of-recurrent-ovarian-cancer-301367853.html
SOURCE Quest PharmaTech Inc.
